GTS Securities’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

GTS Securities’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-120,121	Closed	-$153K	–	4565
2023 Q3	$153K	Buy	+120,121	New	+$105K	﹤0.01%	3502

GTS Securities's ZYNE Position: Q4 2023 in Review

GTS Securities sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 120,121 shares — an estimated $153K sold.

GTS Securities first reported a position in ZYNE in Q3 2023 and held it in 1 quarter. The position peaked at $153K in Q3 2023. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

GTS Securities reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 120,121 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $153K.
GTS Securities first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2023 and held it in 1 quarter.
GTS Securities's Zynerba Pharmaceuticals, Inc position peaked at $153K in Q3 2023.
0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.